Biotricity CEO Discusses Calculated Growth Strategy in Audio Interview with SmallCapVoice.com
Biotricity Inc. (OTCQB: BTCY) announced a new interview featuring CEO Dr. Waqaas Al-Siddiq, discussing the company's innovative cardiac monitoring solutions. The flagship product, Bioflux®, is a wearable device enabling real-time cardiac patient monitoring. Biotricity's growth strategy includes expanding its sales presence across 20 U.S. states, building a sales force, and launching new products. Dr. Al-Siddiq emphasizes the company’s focus on technology over clinical practices, reinforcing a recurring revenue model aimed at enhancing long-term value for investors.
- Biotricity's Bioflux® device targets a multi-billion-dollar cardiac monitoring market.
- The company plans to expand its sales force and product offerings.
- The in-house production of devices allows for cost savings and recurring revenue growth.
- None.
AUSTIN, Texas, March 16, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering disruptive solutions to the multi-billion-dollar cardiac monitoring and diagnostic market.
Biotricity’s flagship Bioflux® product is a wearable medical device that enables physicians to accurately monitor and diagnose cardiac patients in real-time for effective treatment and pain management. While this technology alone targets a massive demographic, the Company’s full pipeline of remote cardiac monitoring and diagnostic solutions provides access to a multi-billion-dollar market hungry for digital innovation.
Speaking with SCV’s Stuart Smith, Dr. Al-Siddiq describes how Biotricity builds and delivers its technology to benefit patients, care providers and the broader healthcare industry, while building long-term value for the Company.
“What we’ve noticed primarily across healthcare, is that technology is owned by clinical players – players that are actually performing the diagnostic tests,” he says. “Our model is very different. We want to enable physicians, hospitals and organizations to do that work so we can stay focused on things of a technology company.”
Biotricity’s monitoring devices are built in-house and are reusable, which saves on costs and enables exponential revenue growth through a recurring technology fee and greater market reach.
“That’s where we have been really fortunate to have a cycle of growth over growth,” explains Dr. Al-Siddiq. “We have a sales force, and the idea is for us to continue to open up more clinics, more hospitals, and get our devices into more hands.”
Biotricity currently has a sales presence in 20 U.S. states. Near-term growth plans include launching more products from the Company’s pipeline and expanding its sales force to target a larger addressable market.
“The most successful medical device and pharma companies have a direct sales force in their key markets and then they have distribution elsewhere,” says Dr. Al-Siddiq. “We are following the exact same track.”
Dr. Al-Siddiq also highlights the experience of Biotricity’s staff and how it was able to leverage that expertise to stride through the challenges of the pandemic and meet demand for remote monitoring.
“Intelligent monitoring and the value of it became very, very clear because of the pandemic,” he says. “The awareness and the need for it increased. The ability to sell was of course limited, but despite that, we were able to grow … Once this pandemic is more under control, I think it’s going to actually crate a boost in our growth in the long term.”
As the Company ramps up its sales force, it is also focused on the release of a new product and uplisting to a national exchange for greater visibility. Of significance, says Dr. Al-Siddiq, is for investors to remember Biotricity’s application to the healthcare industry and how that affects revenues.
“We are a technology company, not a clinical company,” he tells Smith. “Our focus is providing technology to physicians and healthcare companies in a business model that is anchored in reimbursement and a reoccurring revenue model. That is something that creates and accelerated growth and gives us a very high value long term. Being a technology player with a reoccurring business model places us at the top of the food chain when it comes to how to value the company. And we’ve done that in a very specific and concerted way.”
The full interview can be heard at: https://www.smallcapvoice.com/interview-biotricity-btcy/.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
About SmallCapVoice.com
SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.
Socialize with SmallCapVoice and their clients at
Facebook: https://www.facebook.com/SmallCapVoice/
Twitter: https://twitter.com/smallcapvoice
Instagram: https://www.instagram.com/smallcapvoice/
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives, and goals of management for future operations, including plans, objectives, or goals relating to the design, development, and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Biotricity Contacts:
Investor Relations
1-800-590-4155
Investors@Biotricity.com
Todd Kehrli or Mark Forney
MKR Investor Relations, Inc.
BTCY@MKR-Group.com
SmallCapVoice.com Contact:
Stuart T. Smith
512-267-2430
Info@SmallCapVoice.com
Source: SmallCapVoice.com
